FLAVONE ACETIC-ACID AND PLASMA-PROTEIN BINDING

被引:7
作者
BRODFUEHRER, J
VALERIOTE, F
CHAN, K
HEILBRUN, L
CORBETT, T
机构
[1] Division of Hematology and Oncology, Department of Internal Medical, Wayne State University, Detroit, 48 202, MI
关键词
D O I
10.1007/BF00689272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Both the capacity of healthy human, cancer patient, and mouse plasma proteins to bind flavone acetic acid (FAA) and the qualitative differences in the plasma protein-binding site were studied. The binding capacity of plasma proteins for FAA was saturated within the therapeutic range in both species. The binding of FAA to plasma protein was significantly greater in both healthy human and cancer patient plasma than in mouse plasma. Plasma from patients with cancer bound on the average less FAA than did healthy patient plasma. The concentration of albumin in the plasma varied between healthy humans, cancer patients, and mice, being 5.3±0.7, 4.7±0.8, and 3.9±0.3 g/100 ml, respectively. The protein binding of FAA was found to be dependent on the plasma albumin concentration, but albumin concentration alone was not adequate for the accurate prediction of the percentage of FAA protein bound. Scatchard plots indicated that healthy human plasma had a greater number of high-affinity binding sites than did mouse plasma. FAA binds at the indolebenzodiazepine binding area on albumin and can be displaced from this site by salicylic acid and clofibric acid, but only at supratherapeutic concentrations. Our results indicate that alterations in plasma albumin could contribute to a variable effect with FAA. Therefore, the influence of serum albumin concentration and the nonlinearity of FAA protein binding should be considered in assessment of the appropriateness of a dose schedule for FAA. © 1990 Springer-Verlag.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 32 条
[1]   FACTORS INVOLVED IN THE ANTICANCER ACTIVITY OF THE INVESTIGATIONAL AGENTS LM985 (FLAVONE ACETIC-ACID ESTER) AND LM975 (FLAVONE ACETIC-ACID) [J].
BIBBY, MC ;
DOUBLE, JA ;
PHILLIPS, RM ;
LOADMAN, PM .
BRITISH JOURNAL OF CANCER, 1987, 55 (02) :159-163
[2]  
BISSERY MC, 1988, CANCER RES, V48, P1279
[3]   ANTIPROLIFERATIVE PROPERTIES OF FLAVONE ACETIC-ACID (NSC-347512) (LM-975), A NEW ANTICANCER AGENT [J].
CAPOLONGO, LS ;
BALCONI, G ;
UBEZIO, P ;
GIAVAZZI, R ;
TARABOLETTI, G ;
REGONESI, A ;
YODER, OC ;
DINCALCI, M .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (10) :1529-1535
[4]   COULD INTERSPECIES DIFFERENCES IN THE PROTEIN-BINDING OF FLAVONE ACETIC-ACID CONTRIBUTE TO THE FAILURE TO PREDICT LACK OF EFFICACY IN PATIENTS [J].
CASSIDY, J ;
KERR, DJ ;
SETANOIANS, A ;
ZAHARKO, DS ;
KAYE, SB .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (06) :397-400
[5]   INDUCTION OF NATURAL-KILLER CELL-ACTIVITY BY THE ANTITUMOR COMPOUND FLAVONE ACETIC-ACID (NSC-347-512) [J].
CHING, LM ;
BAGULEY, BC .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (07) :1047-1050
[6]  
Cody V., 1986, PLANT FLAVONOIDS BIO
[7]   RANK TRANSFORMATIONS AS A BRIDGE BETWEEN PARAMETRIC AND NONPARAMETRIC STATISTICS [J].
CONOVER, WJ ;
IMAN, RL .
AMERICAN STATISTICIAN, 1981, 35 (03) :124-129
[8]  
CORBETT TH, 1986, INVEST NEW DRUG, V4, P207
[9]   FLAVONE 8-ACETIC ACID - OUR CURRENT UNDERSTANDING OF ITS MECHANISM OF ACTION IN SOLID TUMORS [J].
CUMMINGS, J ;
SMYTH, JF .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 24 (05) :269-272
[10]  
CUMMINGS J, 1989, CANCER RES, V49, P3587